Empowering Schizophrenia Community: Live Your PosSCZible Campaign with Bristol Myers Squibb and Taye Diggs
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative developed in collaboration with the schizophrenia community. The campaign aims to amplify firsthand experiences and…
Live Your PosSCZible Campaign: Bristol Myers Squibb, Taye Diggs, and Schizophrenia Community Unite to Empower Individuals with Schizophrenia
Bristol Myers Squibb (NYSE: BMY) has unveiled the Live Your PosSCZible campaign, a nationwide initiative in collaboration with the schizophrenia community. The campaign aims to amplify personal experiences, offering educational…
AstraZeneca Aims for $80 Billion in Revenue by 2030 with Continued Growth Beyond
Today, AstraZeneca unveiled its ambitious target to achieve $80 billion in Total Revenue by 2030, a significant increase from the $45.8 billion reported in 2023. This expansion will be fueled…
AstraZeneca Announces $1.5 Billion Facility for Antibody Drug Conjugates (ADCs) Manufacturing in Singapore
AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply…
FDA Grants Breakthrough Status to Roche’s Inavolisib for Advanced HR+, HER2- Breast Cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. This…
Nurse Leads Clinical Trials for Innovative Cancer Therapies
Several years ago, Melissa Martinez was watching her youngest daughter’s basketball game when a player had a seizure. With no one else knowing how to help, Martinez’s daughter shouted, “My…
Over Half of Crohn’s Patients Achieve Remission with Lilly’s Mirikizumab at One Year
Eli Lilly’s Mirikizumab Shows Promise in Phase 3 Study for Crohn’s Disease In Eli Lilly and Company’s pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn’s disease,…
Upneeq® Clinches 2024 Shape Skin Award for ‘Best Lift’ in the Professional Treatment Category
RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition,…
Bluebird Bio Investor Alert: Class Action Lawsuit Deadline Approaching
Kirby McInerney LLP is reminding investors of the upcoming May 28, 2024 deadline to seek lead plaintiff status in a federal securities class action related to bluebird bio, Inc. (NASDAQ:…
Guardant Health Discloses Inducement Awards in Accordance with Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a prominent player in precision oncology, disclosed today that its Compensation Committee, on April 22, 2024, sanctioned the allocation of restricted stock units (“RSUs”) corresponding…
Brenmiller’s Project Pipeline Surges to 49 Projects, Encompassing Over $500 Million Potential Value in 12 Industries Across 13 Countries
The leading developer in thermal energy storage (“TES”) globally, Brenmiller, announced significant expansion in its project pipeline, marking a record level for the Company. As of May 1, 2024, Brenmiller…
MAIA Biotechnology Set to Showcase at the 2024 BIO International Convention
MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from…